Sushrut D. Shah

Sushrut D. Shah

Auto-generated profile, based on publicly available information

Sushrut D. Shah

Center for Translational Medicine, Jane and Leonard Korman Respiratory Institute Thomas Jefferson University Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SSSushrut D. Shah
Sushrut D. Shah
CLChristoffer Lind
Christoffer Lind
FPFrancesco De Pascali
Francesco De Pascali
RPRaymond B. Penn
Raymond B. Penn
AMAlexander MacKerell
Alexander MacKerell
DDDeepak Deshpande
Deepak Deshpande
Activation of β 2 -adrenoceptors (β 2 ARs) causes airway smooth muscle (ASM) relaxation and bronchodilation, and β 2 AR agonists (β-agonists) are front-line treatments for asthma and other obstructive lung diseases. However, the therapeutic efficacy of β-agonists is limited by agonist-induced β 2 AR desensitization and noncanonical β 2 AR signaling involving β-arrestin that is shown to promote asthma pathophysiology. Accordingly, we undertook the identification of an allosteric site on β 2 AR that could modulate the activity of β-agonists to overcome these limitations. We employed the site identification by ligand competitive saturation (SILCS) computational method to comprehensively map the entire 3D structure of in silico-generated β 2 AR intermediate conformations and identified a putative allosteric binding site. Subsequent database screening using SILCS identified drug-like molecules with the potential to bind to the site. Experimental assays in HEK293 cells (expressing recombinant wild-type human β 2 AR) and human ASM cells (expressing endogenous β 2 AR) identified positive and negative allosteric modulators (PAMs and NAMs) of β 2 AR as assessed by regulation of β-agonist-stimulation of cyclic AMP generation. PAMs/NAMs had no effect on β-agonist-induced recruitment of β-arrestin to β 2 AR- or β-agonist-induced loss of cell surface expression in HEK293 cells expressing β 2 AR. Mutagenesis analysis of β 2 AR confirmed the SILCS identified site based on mutants of amino acids R131, Y219, and F282. Finally, functional studies revealed augmentation of β-agonist-induced relaxation of contracted human ASM cells and bronchodilation of contracted airways. These findings identify a allosteric binding site on the β 2 AR, whose activation selectively augments β-agonist-induced Gs signaling, and increases relaxation of ASM cells, the principal therapeutic effect of β-agonists.

1 January 2023 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
SSSushrut D. Shah
Sushrut D. Shah
ANAjay P Nayak
Ajay P Nayak
PSPawan Sharma
Pawan Sharma
DVDominic R. Villalba
Dominic R. Villalba
SASankar Addya
Sankar Addya
DDDeepak Deshpande
Deepak Deshpande
ERK1/2 (extracellular signal-regulated kinases 1 and 2) regulate the activity of various transcription factors that contribute to asthma pathogenesis. Although an attractive drug target, broadly inhibiting ERK1/2 is challenging because of unwanted cellular toxicities. We have identified small molecule inhibitors with a benzenesulfonate scaffold that selectively inhibit ERK1/2-mediated activation of AP-1 (activator protein-1). Herein, we describe the findings of targeting ERK1/2-mediated substrate-specific signaling with the small molecule inhibitor SF-3–030 in a murine model of house dust mite (HDM)-induced asthma. In 8- to 10-week-old BALB/c mice, allergic asthma was established by repeated intranasal HDM (25 μg/mouse) instillation for 3 weeks (5 days/week). A subgroup of mice was prophylactically dosed with 10 mg/kg SF-3–030/DMSO intranasally 30 minutes before the HDM challenge. Following the dosing schedule, mice were evaluated for alterations in airway mechanics, inflammation, and markers of airway remodeling. SF-3–030 treatment significantly attenuated HDM-induced elevation of distinct inflammatory cell types and cytokine concentrations in BAL and IgE concentrations in the lungs. Histopathological analysis of lung tissue sections revealed diminished HDM-induced pleocellular peribronchial inflammation, mucus cell metaplasia, collagen accumulation, thickening of airway smooth muscle mass, and expression of markers of cell proliferation (Ki-67 and cyclin D1) in mice treated with SF-3–030. Furthermore, SF-3–030 treatment attenuated HDM-induced airway hyperresponsiveness in mice. Finally, mechanistic studies using transcriptome and proteome analyses suggest inhibition of HDM-induced genes involved in inflammation, cell proliferation, and tissue remodeling by SF-3–030. These preclinical findings demonstrate that function-selective inhibition of ERK1/2 signaling mitigates multiple features of asthma in a murine model.

Verified
Journal Article
Open access
PDF file
MHMiguel Angel Hernandez-Lara
Miguel Angel Hernandez-Lara
Santosh Kumar YadavSantosh Kumar Yadav
Santosh Kumar Yadav
SSSushrut D. Shah
Sushrut D. Shah
MOMariko Okumura
Mariko Okumura
YYYuichi Yokoyama
Yuichi Yokoyama
DDDeepak Deshpande
Deepak Deshpande
Airway remodeling in asthma involves the hyperproliferation of airway smooth muscle (ASM) cells. However, the molecular signals that regulate ASM growth are not completely understood. Gq-coupled G protein-coupled receptor and receptor tyrosine kinase signaling regulate ASM cell proliferation via activation of phospholipase C, generation of inositol triphosphate (IP3) and diacylglycerol (DAG). Diacylglycerol kinase (DGK) converts DAG into phosphatidic acid (PA) and terminates DAG signaling while promoting PA-mediated signaling and function. Herein, we hypothesized that PA is a pro-mitogenic second messenger in ASM, and DGK inhibition reduces the conversion of DAG into PA resulting in inhibition of ASM cell proliferation. We assessed the effect of pharmacological inhibition of DGK on pro-mitogenic signaling and proliferation in primary human ASM cells. Pretreatment with DGK inhibitor I (DGKI) significantly inhibited platelet-derived growth factor-stimulated ASM cell proliferation. Anti-mitogenic effect of DGKI was associated with decreased mTOR signaling and expression of cyclin D1. Exogenous PA promoted pro-mitogenic signaling and rescued DGKI-induced attenuation of ASM cell proliferation. Finally, house dust mite (HDM) challenge in wild type mice promoted airway remodeling features, which were attenuated in DGKζ-/- mice. We propose that DGK serves as a potential drug target for mitigating airway remodeling in asthma.

18 July 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
Santosh Kumar YadavSantosh Kumar Yadav
Santosh Kumar Yadav
PSPawan Sharma
Pawan Sharma
SSSushrut D. Shah
Sushrut D. Shah
RPReynold A. Panettieri
Reynold A. Panettieri
TKTaku Kambayashi
Taku Kambayashi
DDDeepak Deshpande
Deepak Deshpande

1 October 2025 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
SSSushrut D. Shah
Sushrut D. Shah
DDDeepak Deshpande
Deepak Deshpande
The obstructive lung diseases (OLDs), such as asthma and chronic obstructive pulmonary disease (COPD) are characterized by bronchoconstriction and difficulty in breathing. β2-adrenergic receptor (β2AR) agonists (β-agonists) represent the most commonly used class of bronchodilators. To enhance their clinical effectiveness, extensive attempts have been made to improve their receptor subtype selectivity and duration of action, resulting in the development of long-acting β-agonists (LABAs) and ultralong-acting β-agonists. Although these drugs effectively alleviate OLD symptoms, concerns have arisen regarding their safety, their reduced therapeutic benefits, and the potential for worsening asthma symptoms. These concerns have led to restrictions on β-agonist use. Recent advances in G protein–coupled receptor (GPCR) pharmacology and biochemistry have introduced new concepts in drug development, such as “biased agonism” and “allosteric modulation.” These advancements stem from a deeper understanding of the molecular interactions between β2ARs and various intracellular proteins (e.g., heterotrimeric G proteins and β-arrestins), which induce a diverse array of functional changes in airway cells. Biased agonism and allosteric modulation offer new avenues for developing the next generation of β-agonists with improved pharmacological properties. This review explores the application of these concepts in developing new β2AR ligands, including orthosteric and allosteric ligands, that selectively enhance therapeutically beneficial Gs signaling while minimizing harmful β-arrestin–mediated effects in airway cells.

24 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMegumi Shigematsu
Megumi Shigematsu
AMAtsushi Minami
Atsushi Minami
TKTakuya Kawamura
Takuya Kawamura
SSSushrut D. Shah
Sushrut D. Shah
TOTetsuhiro Ogawa
Tetsuhiro Ogawa
KPKamlesh Pawar
Kamlesh Pawar
The RNase A superfamily, one of the most extensively studied enzyme families, remains incompletely defined with respect to its endogenous RNA substrates, recognition mechanisms, and physiological functions. Here, we identify eosinophil-derived neurotoxin (EDN/RNase 2) as a principal endoribonuclease mediating tRNA cleavage in the asthmatic lung. Inhalation of house dust mite (HDM) in mice induces robust accumulation of tRNA halves in the lung, coinciding with exclusive upregulation of EDN, but not other ribonucleases. In human lung epithelial cells, internalized EDN cleaves specific tRNAs and generates multiple species of tRNA halves, including immunostimulatory species that activate Toll-like receptor 7 (TLR7). EDN also promotes the release of extracellular vesicles enriched in these RNAs, implicating them in cytokine production during asthma pathogenesis. Biochemical analyses and structural simulations reveal that EDN recognizes the anticodon loop of tRNA by anchoring the phosphate backbones flanking the cleavage site, thereby precisely positioning the C34–A35 phosphodiester bond for catalysis. Furthermore, the highly efficient cleavage by EDN is mediated by conserved elements, including Arg36 in EDN and U33 and C38 in the target tRNA. Together, these findings establish the endogenous RNA substrate of EDN and uncover a molecular mechanism that links RNase A superfamily activity to immune response.